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background:  Almost all patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) and elevated troponin are managed with invasive 
procedures. There is limited information on risk evaluation in these patients. We investigated if clinical variables, extent of coronary artery disease 
(CAD) and biomarkers at entry might be useful for risk stratification.
methods: In the PLATO study, 5,241 NSTE-ACS patients underwent revascularization during index hospitalization and had hs-TnT, NT-proBNP, and 
GDF-15 levels measured from plasma samples obtained at entry. Cox proportional hazards models were developed adding extent of CAD and levels 
of biomarkers to established clinical risk variables for the composite endpoint of cardiovascular death (CVD)/spontaneous myocardial infarction 
(MI), and for CVD alone. Models were compared using C-statistic and net reclassification index (NRI).
results: Prediction of the composite endpoint was improved by adding CAD to clinical variables (C-index increased from 0.659 to 0.676, NRI 
0.174, p<0.0001). TnT was not included in the model as it did not change risk prediction. Adding NTproBNP and GDF-15 improved prediction both of 
the composite endpoint and of CVD alone (see table). GDF-15 contributed mainly by reclassification of patients to a lower risk.
Conclusion: NT-proBNP and GDF-15 but not TnT levels at entry contribute to risk stratification beyond clinical variables and extent of CAD in 
revascularized patients with NSTE-ACS. 
 
Outcome C index NRI Total NRI Among events NRI Among non-events p-value LR test
Cardiovascular death (CVD)/Spontaneous MI
Model 1: Clinical variables + CAD 0.676
Model 1 + NT-proBNP 0.682 0.18765 0.14089 0.04676 <.0001
Model 1 + GDF-15 0.684 0.18533 0.00802 0.17730 <.0001
Model 2: Clinical variables + CAD + NTproBNP 0.682
Model 2 + GDF-15 0.686 0.12377 0.01999 0.10378 0.0027
CVD alone
Model 1: Clinical variables + CAD 0.780
Model 1 + NT-proBNP 0.789 0.44460 0.28598 0.15863 <.0001
Model 1 + GDF-15 0.791 0.27157 0.04496 0.22661 <.0001
Model 2: Clinical variables + CAD + NTproBNP 0.789
Model 2 + GDF-15 0.793 0.09210 0.04411 0.04798 0.0101
